TransMedics Sets 2026 Revenue Guidance at $764 Million to $774 Million Including PAD

TransMedics Group, Inc. raised its 2026 revenue guidance to $764M-$774M, up from $737M-$757M. The new range includes $14M from PAD Aviation. CEO Waleed Hassanein noted Q3 2026 was the company's strongest quarter for revenue and case volume.

Original reporting
Published Nov 7, 2026, 8:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 8, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TransMedics Sets 2026 Revenue Guidance at $764 Million to $774 Million Including PAD — source image
Decision brief

The 30-second read

Med
01

Why it matters

The guidance lift suggests improved sales momentum and case volume growth.

02

Market read

First report of 2026 guidance, modestly better than prior range, may influence TMED price.

03

What to watch

Potential regulatory or reimbursement risks could offset the guidance lift.

Relevance 7/10Novelty 7/10Timing: today

Background

TransMedics Group provides organ perfusion technologies for transplant procedures.

Market effects

May lift sentiment for the broader organ transplant and medical device sector.

Limited to U.S. biotech investors.

Low, as the company is niche.

Counterpoint

Guidance increase is modest; market may have already priced in the upside.

Key entities

  • Waleed Hassanein

    President and CEO of TransMedics who announced the guidance.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.